Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedNov 24, 2025
DataAggregated Company Financials
Companies543
  • 7D4.4%
  • 3M24.8%
  • 1Y17.5%
  • YTD26.9%

The Biotech industry is up 4.4% in the last week, with Regeneron Pharmaceuticals up 12%. This takes the industry's 12 month performance to a gain of 18%. As for the next few years, earnings are expected to grow by 24% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 27 Nov 2025US$1.2tUS$163.8b-US$16,230,751,145.9818.2x-74.3x7.4x
Sat, 25 Oct 2025US$1.2tUS$163.4b-US$18,534,573,619.1017.3x-62.5x7.1x
Mon, 22 Sep 2025US$1.1tUS$163.5b-US$18,307,901,758.9716.3x-59.2x6.6x
Wed, 20 Aug 2025US$1.1tUS$163.6b-US$18,817,514,396.7516.8x-56.9x6.5x
Fri, 18 Jul 2025US$983.5bUS$155.7b-US$23,413,712,907.2616.5x-42x6.3x
Sun, 15 Jun 2025US$949.1bUS$155.9b-US$23,959,829,667.0016.3x-39.6x6.1x
Tue, 13 May 2025US$865.3bUS$155.1b-US$24,600,766,978.0516.9x-35.2x5.6x
Thu, 10 Apr 2025US$704.8bUS$118.6b-US$36,908,648,987.1921.5x-19.1x5.9x
Sat, 08 Mar 2025US$845.1bUS$119.0b-US$37,271,574,129.9917.2x-22.7x7.1x
Mon, 03 Feb 2025US$1.0tUS$149.5b-US$26,306,804,829.5717.2x-38.1x6.7x
Wed, 01 Jan 2025US$960.8bUS$149.6b-US$26,363,797,961.5216.9x-36.4x6.4x
Fri, 29 Nov 2024US$1.0tUS$150.0b-US$26,596,552,206.0116.6x-39.1x6.9x
Sun, 27 Oct 2024US$888.6bUS$113.1b-US$36,033,068,263.0120.6x-24.7x7.9x
Tue, 24 Sep 2024US$920.0bUS$113.2b-US$35,983,947,157.4121.9x-25.6x8.1x
Thu, 22 Aug 2024US$903.8bUS$113.2b-US$35,868,195,932.5623.3x-25.2x8x
Sat, 20 Jul 2024US$1.2tUS$164.5b-US$28,047,850,966.8929x-42.5x7.3x
Mon, 17 Jun 2024US$1.2tUS$164.4b-US$27,941,797,208.3727.3x-41.4x7x
Wed, 15 May 2024US$1.1tUS$164.6b-US$27,141,970,719.5427.5x-41.5x6.8x
Fri, 12 Apr 2024US$1.1tUS$164.3b-US$23,380,537,394.4821x-48x6.8x
Sun, 10 Mar 2024US$1.2tUS$167.3b-US$22,140,783,177.0319x-53.9x7.1x
Tue, 06 Feb 2024US$1.3tUS$196.1b-US$18,610,955,456.9217.5x-70.8x6.7x
Thu, 04 Jan 2024US$1.4tUS$204.8b-US$22,306,519,032.0020.9x-63.4x6.9x
Sat, 02 Dec 2023US$1.3tUS$204.7b-US$22,044,035,456.0019x-56.7x6.1x
Mon, 30 Oct 2023US$1.2tUS$206.6b-US$15,116,353,891.0016.3x-78x5.7x
Wed, 27 Sep 2023US$1.3tUS$207.4b-US$12,903,835,924.0017.2x-98.3x6.1x
Fri, 25 Aug 2023US$1.3tUS$207.6b-US$12,461,259,012.0017.3x-102.1x6.1x
Sun, 23 Jul 2023US$1.2tUS$186.6b-US$16,026,393,300.0012.8x-72x6.2x
Tue, 20 Jun 2023US$1.2tUS$186.3b-US$16,029,005,553.0012.1x-72.4x6.2x
Thu, 18 May 2023US$1.1tUS$186.1b-US$15,822,861,311.0013.3x-72.4x6.2x
Sat, 15 Apr 2023US$1.2tUS$198.5b-US$3,247,497,685.0014.1x-361.6x5.9x
Mon, 13 Mar 2023US$1.1tUS$199.3b-US$4,753,099,202.0014.9x-230.1x5.5x
Wed, 08 Feb 2023US$1.2tUS$202.3bUS$1.4b16.5x806.8x5.8x
Fri, 06 Jan 2023US$1.2tUS$203.1bUS$1.5b14.4x751.8x5.7x
Sun, 04 Dec 2022US$1.2tUS$202.6bUS$1.4b15.1x842.2x5.8x
Price to Earnings Ratio

842.2x


Total Market Cap: US$1.2tTotal Earnings: US$1.4bTotal Revenue: US$202.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 6.9x202320242025
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.5x is lower than the industry's current PS ratio of 7.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 6.8% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market2.86%
Healthcare4.73%
Biotech4.38%
Biotech4.38%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
REGN Regeneron PharmaceuticalsUS$784.6111.6%
+US$8.4b		3.9%PE17.6x
EXAS Exact SciencesUS$101.4517.7%
+US$2.9b		64.5%PS6.2x
VRTX Vertex PharmaceuticalsUS$432.172.6%
+US$2.8b		-7.0%PE29.8x
NTRA NateraUS$237.128.6%
+US$2.6b		40.8%PS15.5x
ARWR Arrowhead PharmaceuticalsUS$57.7148.1%
+US$2.4b		120.7%PS9.4x

Latest News

ONC
US$340.64
BeOne Medicines
7D
-3.7%
1Y
65.2%
ARWR
US$57.71
Arrowhead Pharmaceuticals
7D
48.1%
1Y
120.7%
IONS
US$82.70
Ionis Pharmaceuticals
7D
11.8%
1Y
130.4%

IONS: Upcoming Late-Stage Data and Recent Regulatory Progress Will Shape Balanced Outlook

Ionis Pharmaceuticals’ analyst price target has been raised from approximately $82 to $85 per share. This reflects analyst optimism following strong Phase 3 trial results, upward sales guidance, and an improved clinical and commercial outlook across multiple pipeline programs.
REGN
US$784.61
Regeneron Pharmaceuticals
7D
11.6%
1Y
3.9%
EXAS
US$101.45
Exact Sciences
7D
17.7%
1Y
64.5%
ABBV
US$227.66
AbbVie
7D
-2.3%
1Y
24.3%

ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections

AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.
GILD
US$127.51
Gilead Sciences
7D
-0.4%
1Y
38.0%

GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures

Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.
BIIB
US$181.94
Biogen
7D
8.3%
1Y
13.8%
NTRA
US$237.12
Natera
7D
8.6%
1Y
40.8%
PGEN
US$3.74
Precigen
7D
-11.4%
1Y
311.3%
ASND
US$210.01
Ascendis Pharma
7D
-1.0%
1Y
54.1%
VRTX
US$432.17
Vertex Pharmaceuticals
7D
2.6%
1Y
-7.0%
ACLX
US$73.25
Arcellx
7D
-18.3%
1Y
-17.8%
RVMD
US$77.58
Revolution Medicines
7D
11.0%
1Y
32.4%
MCRB
US$16.87
Seres Therapeutics
7D
-41.1%
1Y
-7.8%
NNNN
US$22.59
Anbio Biotechnology
7D
-18.1%
1Y
n/a